This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GSK, Pfizer deal goes to in-depth Phase 2 review in the Philippines

( May 6, 2019, 06:18 GMT | Official Statement) -- MLex Summary: GlaxoSmithKline's proposed takeover of Pfizer's global consumer healthcare business will undergo a more in-depth Phase 2 review from the Philippine Competition Commission. The commission's initial 30-day preliminary review that ended on April 22 found indications that the transaction may affect the markets for antitussive and expectorants, analgesics and nutritive health products. The merger review office will continue its market investigation for up to 60 more calendar days.The commission's full statement is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections